Of all the therapies during the neonatal period, none has probably been tested as extensively as surfactant replacement therapy. More than 400 clinical trials have evaluated the overall efficacy of ...

Surfactant dysfunction may contribute to the development of bronchopulmonary dysplasia (BPD) in persistently ventilated preterm infants. We conducted a multicenter randomized, blinded, pilot study to ...

Objective: Recently, natural exogenous surfactant replacement has been used in experimental models and clinical trials for the treatment of severe respiratory syncytial virus (RSV) disease. The ...

Surfactant replacement therapy, delivers a liquid medication for premature neonates and adults with lung injuries. The surfactant helps in lung inflation. The ability of a lung to accept medication ...

Surfactant therapy has become a routine for neonatal respiratory care and already proved to reduce morbidity and mortality in neonatal respiratory distress syndrome. The surfactant replacement has ...

RDS or neonatal respiratory distress syndrome affects the premature babies adversely Reuters The Food and Drug Administration (FDA) has approved Surfaxin (lucinactant) to treat Respiratory Distress ...

A new study reveals how lower temperatures improve the activity of surfactant, a molecular mixture that is essential for breathing. This indicates that therapeutic hypothermia is a potential treatment ...

To the Editor: The phase 3 studies on the effect of recombinant surfactant protein C in the acute respiratory distress syndrome, reported by Spragg et al. (Aug. 26 issue), 1 address an important ...

SURFAXIN (lucinactant) 8.5mL intratrachial suspension by Discovery Laboratories Discovery Laboratories announced its launch of Surfaxin (lucinactant) Intratracheal Suspension for the prevention of ...

SURFAXIN is the First FDA-Approved Synthetic, Peptide-Containing Surfactant WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology ...